This quarter

cagrisema is waiting for an fda decision — and it arrived with a complicated record

Novo Nordisk filed its New Drug Application for CagriSema on December 18, 2025. The FDA is expected to issue a decision on the obesity drug before the end of 2026 — meaning November is inside the review window. CagriSema is a once-weekly fixed-dose combination of semaglutide 2.4 mg and cagrilintide 2.4 mg, two distinct molecules attacking satiety through separate biological pathways. The clinical record going into that decision reads like a complicated negotiation with expectations: the drug beat semaglutide in every head-to-head trial, produced as much as 22.7% placebo-adjusted weight loss in REDEFINE 1, and then arrived at a daring open-label comparison against tirzepatide in February 2026 — and lost. [BioSpace reported the REDEFINE 4 result on February 23](https://www.biospace.com/drug-development/novos-cagrisema-falls-to-lillys-zepbound-in-daring-head-to-head-test): CagriSema produced 20.2% weight loss versus 23.6% with tirzepatide under the treatment-regimen estimand, missing the non-inferiority threshold the trial was designed to establish. The FDA has the full record now. The semaglutide component is well known. The cagrilintide part is not.

The molecule

cagrilintide is what happens when pharmaceutical engineering spends 20 years on amylin

Amylin is a 37-amino-acid peptide co-secreted from pancreatic beta cells alongside insulin in response to meals. It acts through receptors in the brainstem — particularly the area postrema and nucleus tractus solitarius — to slow gastric emptying, suppress post-meal glucagon release, and reduce food intake through central satiety signaling. That biology has been understood for decades. The first clinical translation was pramlintide, a stabilized amylin analog approved by the FDA in 2005 for use alongside insulin in type 1 and type 2 diabetes. It worked, but required multiple daily injections and never became a major commercial story. Cagrilintide is the next engineering step: a long-acting amylin analog with modifications that allow once-weekly subcutaneous dosing. The fundamental rationale for combining it with semaglutide is biological synergy — GLP-1 receptor agonism and amylin receptor signaling are distinct pathways, and the hypothesis is that activating both produces additive satiety beyond what either achieves alone. [PubMed cagrilintide literature](https://pubmed.ncbi.nlm.nih.gov/?term=cagrilintide) covers the pharmacokinetics and early endocrine data that confirmed the combination signal in human trials.

The pitch

the internet framed cagrisema as the next ozempic — the expectation was 25% weight loss

The public framing of CagriSema has been shaped almost entirely by the weight-loss percentage story. Novo Nordisk set a 25% placebo-adjusted weight-loss target as its own public ambition, which became the benchmark against which every result was measured — not by regulators, but by financial analysts, obesity medicine forums, and the GLP-1 commentary class. REDEFINE 1 came in at 22.7%. That number exceeds the clinical magnitude of approved semaglutide and tirzepatide in several earlier head-to-head trial contexts, but it was judged against the internal target rather than the actual efficacy of the nearest competitor. The practical translation in wellness circles became simple: CagriSema is a stronger version of Ozempic, arriving at a moment when every GLP-1 conversation orbits weight-loss percentages as though they were sports scores. What that framing erases is what cagrilintide is doing separately from the semaglutide in the combination — and why adding the amylin pathway to a GLP-1 therapy represents a distinct biological bet, not just a dose increase.

What the data says

phase 3 showed it beats wegovy — the tirzepatide comparison is where it gets complicated

The human evidence record for cagrilintide runs through the REDEFINE and REIMAGINE clinical trials, all of which studied it as part of the CagriSema combination. REDEFINE 1 enrolled adults with obesity or overweight and showed 22.7% placebo-adjusted weight loss at 68 weeks among adherent participants — statistically superior to placebo and to semaglutide alone (16.1%) in the same trial. REDEFINE 2 extended that to type 2 diabetes, with 15.7% weight loss versus 3.1% for placebo. [REIMAGINE 2 results published February 3, 2026](https://www.biospace.com/drug-development/novos-next-gen-obesity-drug-beats-wegovy-on-blood-sugar-control-in-phase-iii) showed CagriSema beating semaglutide on HbA1c reduction (1.91 percentage-point drop versus 1.76) and on weight (14.2% versus 10.2%). REDEFINE 4 then ran an open-label comparison against tirzepatide 15 mg: CagriSema produced 20.2% weight loss versus 23.6% for tirzepatide under the treatment-regimen estimand, and 23% versus 25.5% under the efficacy estimand — missing the non-inferiority threshold. [ClinicalTrials.gov cagrilintide registry](https://clinicaltrials.gov/search?term=cagrilintide) shows two ongoing monotherapy phase 3 trials — RENEW 1 and RENEW 2 — with estimated completion dates in 2027. The cagrilintide-only signal, the question of what the amylin component achieves by itself at this dose range, has not been fully answered by any completed trial.

Early human — PeptideFactCheck stance

the data moves the needle on amylin biology — the approval is about the combination, not the molecule alone

Cagrilintide holds the Early human evidence tier on PeptideFactCheck: interesting enough to watch, too early for broad certainty. That tier reflects what the record actually contains — a molecule with a credible biological rationale backed by one of the oldest endogenous satiety-peptide stories in metabolic medicine, with phase 3 human data for the combination drug and ongoing phase 3 trials for the monotherapy. The FDA is currently reviewing CagriSema, not cagrilintide as a standalone therapy. If CagriSema is approved before the end of 2026, that decision covers the fixed-dose combination for weight management in adults — it does not constitute approval of cagrilintide itself, which remains investigational in the RENEW phase 3 program through at least 2027. [The FDA unapproved GLP-1 drug concerns page](https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) is the operational boundary for how those distinctions matter in practice. The amylin biology is established. The clinical translation is still being settled. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.